Neutropenia Associated with Quetiapine, Olanzapine, and Aripiprazole

Lander, Matthew; Bastiampillai, Tarun

doi:10.3109/00048674.2010.524624

Cited by 27 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cases have been reported with other antipsychotics 104 , however routine blood testing is only required for clozapine. Nevertheless, besides isolated case reports, no larger case series or studies reporting in the association between APP and leucopenia, neutropenia or agranulocytosis were found in the literature.…”

Section: Resultsmentioning

confidence: 99%

Safety and tolerability of antipsychotic polypharmacy

Gallego

Nielsen

Hert³

et al. 2012

Expert Opinion on Drug Safety

172

142

View full text Add to dashboard Cite

Introduction Antipsychotic polypharmacy (APP), the concomitant use of ≥2antipsychotics, is common in clinical practice. Prior reviews have focused on the efficacy of APP, but no systematic review exists regarding the safety and tolerability of this practice. Areas covered in this review We conducted a systematic review of adverse effects associated with APP. Case series with ≥2 patients, chart reviews, naturalistic, data base, cohort and randomized studies that reported on the association between APP in general or specific APP combinations and global or specific adverse effect were included. We discuss methodological limitations of available studies and provide recommendations for clinicians and future research. Expert Opinion Across mostly small and uncontrolled studies, APP has been associated with increased global side effect burden, rates of Parkinsonian side effects, anticholinergic use, hyperprolactinemia, sexual dysfunction, hypersalivation, sedation/somnolence, cognitive impairment, and diabetes. Effects on akathisia and mortality were inconclusive. Although some combinations, particularly aripiprazole augmentation of an agent with greater side effect burden, may reduce weight gain, dyslipidemia, hyperprolactinemia and sexual dysfunction, APP should remain a last resort treatment option after monotherapy, switching and non-antipsychotic combinations have failed. More and high quality data are needed to further inform the individualized risk-benefit evaluation of APP.

show abstract

Section: Resultsmentioning

confidence: 99%

Safety and tolerability of antipsychotic polypharmacy

Gallego

Nielsen

Hert³

et al. 2012

Expert Opinion on Drug Safety

172

142

View full text Add to dashboard Cite

show abstract

“…Typically, these involved single use of 2 different antipsychotics, clozapine and olanzapine,11 in addition to the combinations of risperidone and clozapine,12 risperidone and aripiprazole,9 and olanzapine and ziprasidone 13. Currently, there is one case report about neutropenia associated with the use of 3 different antipsychotics, quetiapine, olanzapine, and aripiprazole 14. In agreement with this report, we found that the neutrophil count remarkably dropped to 0.63×10 9 /L with quetiapine, 0.98×10 9 /L with olanzapine, 1.17×10 9 /L with risperidone, and 0.97×10 9 /L with aripiprazole after the initial even.…”

Section: Discussionmentioning

confidence: 99%

A Case with Neutropenia Related with the Use of Various Atypical Antipsychotics

Lim

Park

2013

Psychiatry Investig

View full text Add to dashboard Cite

Herein, we report here a case of a 21-year-old patient with a conduct disorder, who had neutropenia associated with treatment with 4 different antipsychotics (olanzapine, quetiapine, risperidone, and aripiprazole) on a sequential basis. This case supports the hypothesis that patients who developed antipsychotic-induced neutropenia on one medication are more likely to develop neutropenia when taking other antipsychotics. Based on this finding, we may suggest that the number of white blood cell and neutrophil counts in patients with a history of antipsychotic-induced neutropenia needs to be carefully monitored during antipsychotic treatment.

show abstract

“…Second, as seen in Case 1, the medication can lead to neutropenia and blood may have to be monitored. The newer atypical antipsychotics are all associated with potential neutropenia though 20 and the other 3 cases reported had neutrophil count values between 3 and 4 thousand/lL throughout their stay. Third, milder cases of AN may well respond to psychotherapy alone.…”

Section: Discussionmentioning

confidence: 99%

Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa—A case series

Frank

2015

Intl J Eating Disorders

View full text Add to dashboard Cite

Anorexia nervosa (AN) is a severe and complex psychiatric disorder and no medication has been approved for its treatment. This case series in youth with severe, recurrent AN supports the hypothesis that dopamine receptor agonists could be helpful in supporting fear extinction during eating disorder focused psychotherapy and therefore support recovery from AN. © 2015 Wiley Periodicals, Inc. (Int J Eat Disord 2016; 49:529-533).

show abstract

Neutropenia Associated with Quetiapine, Olanzapine, and Aripiprazole

Cited by 27 publications

References 4 publications

Safety and tolerability of antipsychotic polypharmacy

Safety and tolerability of antipsychotic polypharmacy

A Case with Neutropenia Related with the Use of Various Atypical Antipsychotics

Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa—A case series

Contact Info

Product

Resources

About